KOSDAQBiotech & Pharma144510

Gc Cell

₩14,520▼ 1.43%2026-10-02 close

Market Cap

₩230.4B

Turnover

₩400M

Volume

30,000 shares

Shares out.

15.8M

PER

—

PBR

1.2×

EPS

-₩16,397

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Losses Persist as Cell Therapy Commercialization Clock Ticks

GC Cell is expanding its NK and CAR-NK cell therapy pipeline on the back of cash flow from its diagnostic-testing and bio-logistics businesses, but consecutive net losses and shrinking equity in 2024-2025 leave commercialization progress as the key variable to watch.

1
FY2025 revenue was KRW 165.5bn with an operating loss of KRW 13.8bn, marking a third straight year of losses, while the owners' net loss widened sharply to KRW 272.9bn
2
In Q2 2026 owners' net profit turned positive at KRW 2.2bn, while the operating loss narrowed from KRW 5.1bn in Q1 to KRW 1.0bn in Q2
3
Reference-lab diagnostic testing accounts for nearly half of revenue, underpinning development of the CD5 CAR-NK candidate GCC2005 and other cell therapy pipeline assets such as AB-101
4
A national health insurance fee-schedule reform set to take effect in December is expected to raise the outsourced-testing fee rate from 40% to 45%, cited as a profitability tailwind
5
FUCASO, the CAR-T therapy licensed in from China's IASO Bio, is undergoing domestic import approval and reimbursement review, targeting a sales launch in the second half of 2027

Business structure

GC Cell is a cell and gene therapy specialist under the GC Biopharma Group, spun off from GC Holdings' biotechnology research institute in 2011.

The business rests on three pillars: reference-lab diagnostic testing, cell therapies (led by Immuncell-LC), and bio-logistics, which accounted for roughly 48.7%, 23.7%, and 18.8% of FY2025 consolidated revenue, respectively.

Immuncell-LC is an autologous anticancer immune cell therapy made by isolating and culturing a patient's own immune cells, approved in 2007 as adjuvant therapy following hepatocellular carcinoma surgery, with cumulative shipments exceeding 97,000 packs and more than 10,400 patients treated.

The diagnostic-testing segment serves hospitals and clinics nationwide and built competitiveness through its COVID-19 testing experience, though revenue declines and cost pressure have kept profitability limited recently.

The cell therapy pipeline includes GCC2005, an allogeneic cord-blood-derived CAR-NK therapy targeting CD5 for relapsed or refractory NK/T-cell lymphoma; AB-201, a HER2-targeted CAR-NK for solid tumors; and AB-101, an allogeneic NK cell therapy for autoimmune disease and hematologic cancers being developed by US affiliate Artiva Biotherapeutics.

The company is also pursuing domestic commercialization of FUCASO, a BCMA-targeted CAR-T therapy licensed from China's IASO Bio.

GC Cell has built an end-to-end CGT value chain spanning R&D, clinical development, manufacturing, storage, delivery, and commercialization, with its Yongin "Cell Center" housing ten clean rooms and annual production capacity of up to 15,000 Immuncell-LC packs.

Its competitive landscape spans domestic large-scale diagnostic laboratories on one side and Korean NK cell therapy developers such as NKMax as well as global CAR-T/CAR-NK players on the other.

Earnings trend

Quarterly revenue · Operating profit

₩43B-₩3.4B25Q2₩45B-₩400M25Q3₩38B-₩4.3B25Q4₩37.4B-₩5.1B26Q1₩41.6B-₩1B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩236.1B₩44.3B2022₩187.5B₩4.1B2023₩174.5B-₩20B2024₩165.5B-₩13.8B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩43B	-₩3.4B	−7.9%
2025Q3	₩45B	-₩400M	−0.9%
2025Q4	₩38B	-₩4.3B	−11.4%
2026Q1	₩37.4B	-₩5.1B	−13.7%
2026Q2	₩41.6B	-₩1B	−2.4%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩236.1B	₩44.3B	₩24.2B	18.8%	4.5%	24.0%
2023	₩187.5B	₩4.1B	₩79,104,926	2.2%	0.0%	22.8%
2024	₩174.5B	-₩20B	-₩73.9B	−11.5%	−16.1%	25.1%
2025	₩165.5B	-₩13.8B	-₩272.9B	−8.3%	−146.4%	59.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21

Earnings analysis

GC Cell's revenue peaked at KRW 236.1bn in 2022 before declining for four consecutive years to KRW 187.5bn in 2023, KRW 174.5bn in 2024, and KRW 165.5bn in 2025.

The operating margin also collapsed from a solid 18.8% in 2022 to 2.2% in 2023, then turned negative for two straight years at -11.5% in 2024 and -8.3% in 2025.

On the net income line, the company posted a KRW 24.2bn profit in 2022 and near breakeven (KRW 79 million) in 2023, before swinging to an owners' net loss of KRW 73.9bn in 2024 that widened dramatically to KRW 272.9bn in 2025.

Quarterly, the operating loss narrowed to roughly KRW 0.4bn in Q3 2025, approaching breakeven, but the Q4 2025 net loss ballooned to KRW 243.0bn, sharply worsening the full-year result.

This Q4 net loss far exceeded the quarter's operating loss of KRW 4.3bn, suggesting a large one-off item outside operations, though the specific cause would require further confirmation through disclosure footnotes.

As a result of these large losses, owners' equity fell from KRW 534.0bn in 2023 to KRW 457.8bn in 2024 and further to KRW 186.4bn in 2025, while the debt ratio rose from 22.8% to 59.5%.

Into 2026, the operating loss narrowed to KRW 5.1bn in Q1 and KRW 1.0bn in Q2, and notably owners' net profit turned positive at KRW 2.2bn in Q2 2026, suggesting the company may be past its low point.

Quarterly revenue moved between roughly KRW 43.0bn (Q2 2025), KRW 45.0bn (Q3 2025), KRW 38.0bn (Q4 2025), KRW 37.4bn (Q1 2026), and KRW 41.6bn (Q2 2026), with fluctuations but no clearly pronounced recovery trend yet.

Industry analysis

The cell and gene therapy (CGT) industry that GC Cell operates in is in an early growth phase where global clinical development and commercialization of CAR-T, CAR-NK, and NK cell therapies are proceeding in parallel.

In Korea, national health insurance policy changes have a direct bearing on the economics of the diagnostic-testing business: a fee-schedule reform set to take effect in December 2026 will shift billing from hospital-mediated claims to direct insurance claims and raise the outsourced-testing fee rate from 40% to 45%, which is viewed as a structural profit driver requiring no additional cost outlay.

Within the cell therapy market, CAR-T treatment has become associated with high-cost, hospital-intensive care, whereas AB-101, the allogeneic, non-genetically-modified NK cell therapy developed by GC Cell's affiliate Artiva, is designed for outpatient administration, seeking differentiation on cost structure and accessibility.

Competitors include domestic NK cell therapy developer NKMax and global CAR-T/CAR-NK developers, while in the domestic CDMO space GC Cell has built a value-chain alliance with Excellgen Therapeutics, Corestem Chemon, Gene Medicine, and GCCL to expand a collaborative ecosystem.

In 2026, GC Cell obtained Cell Processing Center (CPC) certification from Japan's Ministry of Health, Labour and Welfare, recognizing its manufacturing and quality-control capabilities for overseas regulatory requirements, while in Indonesia the establishment of a local production system for Immuncell-LC through a local partner is nearing completion.

Still, since many companies in the broader cell therapy industry have yet to translate pipelines into large-scale commercial revenue, the pace of pipeline clinical data readouts and regulatory approvals remains the key variable shaping individual company valuations.

Outlook

GC Cell's near-term outlook hinges on two tracks: policy tailwinds for the diagnostic-testing business and the clinical/commercialization timeline for its cell therapy pipeline.

First, the health insurance fee-schedule reform taking effect in December 2026 is expected to raise the outsourced-testing fee rate for the reference-lab business, improving margins without additional cost.

In cell therapy, the CD5 CAR-NK candidate GCC2005 recorded a 62.5% objective response rate and a 37.5% complete response rate in an initial cohort of eight patients, and the company plans to release additional clinical data from roughly 18 patients in the second half of 2026.

AB-201, a HER2-targeted CAR-NK, began dosing its first patient at Severance Hospital in May 2026 in gastric and gastroesophageal junction cancer patients, extending the pipeline into solid tumors.

US affiliate Artiva has agreed with the FDA on a single registrational Phase 3 trial design for AB-101 in rheumatoid arthritis, raised USD 300 million in the first half of 2026, and is targeting first-patient dosing in the second half of 2026, key data by the second half of 2028, and an FDA filing in 2029.

FUCASO, the BCMA-targeted CAR-T licensed from China's IASO Bio, had its domestic import approval application filed in February 2026 with reimbursement listing also being pursued, and the company has set a target of launching domestic sales in the second half of 2027 with an eventual revenue goal of KRW 40bn.

Securities analysts have characterized this period as one where policy tailwinds and R&D catalysts converge, with some pointing to the possibility of reaching operating breakeven in 2027.

Valuation

PER

—

PBR

1.2×

ROE

-80.1%

EPS

-₩16,397

BPS

₩12,348

Dividend per share

₩0

GC Cell has posted net losses over the last four quarters, putting the price-to-earnings ratio in a range that is difficult to calculate.

The stock trades at a level above its per-share net asset value, suggesting the market is assigning some premium to the future growth potential of its cell therapy pipeline and CDMO business. The company currently pays no dividend, so dividend-related metrics do not apply.

Given that revenue and operating margin have been on a shrinking trajectory since 2022, how the market values the stock going forward may depend on the pace of profitability recovery in the diagnostic-testing segment and progress in cell therapy commercialization.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21

Bull factors

Margin improvement from the diagnostic-testing fee reform

The health insurance fee-schedule reform set to take effect in December 2026 will raise the diagnostic-testing outsourced fee rate from 40% to 45% and shift billing from a hospital-mediated process to direct insurance claims.

Since this raises profit without additional cost, it could support a profitability recovery in a segment that accounts for nearly half of revenue. Whether the trend of a narrowing operating loss, from KRW 5.1bn in Q1 2026 to KRW 1.0bn in Q2, continues alongside this policy effect is a point worth watching.

Early clinical results across the NK/CAR-NK pipeline

The CD5-targeted CAR-NK candidate GCC2005 recorded a 62.5% objective response rate and a 37.5% complete response rate in an initial eight-patient cohort, with additional data from roughly 18 patients due in the second half of 2026.

AB-201, targeting HER2, expanded the pipeline into solid tumors with its first patient dosed in May 2026. US affiliate Artiva's AB-101 has maintained momentum, agreeing with the FDA on a single registrational Phase 3 design and raising USD 300 million in the first half of 2026.

CGT value-chain positioning and overseas certification

GC Cell has built an end-to-end CGT value chain spanning R&D through manufacturing, storage, delivery, and commercialization, and expanded the ecosystem in 2026 through an alliance with four domestic companies.

That same year it obtained Cell Processing Center (CPC) certification from Japan's Ministry of Health, Labour and Welfare, gaining recognition for its overseas regulatory capabilities.

Discussions on local production and technology transfer for Immuncell-LC are advancing in markets such as Indonesia, potentially serving as a foothold for further overseas expansion.

Bear factors

Four straight years of revenue decline and persistent operating losses

Revenue fell for four consecutive years from KRW 236.1bn in 2022 to KRW 165.5bn in 2025, while the operating margin deteriorated from 18.8% to -8.3% over the same period. Operating losses were recorded in both 2024 and 2025, indicating that the profit base of the core business has weakened.

While a loss-narrowing trend was confirmed in the first half of 2026, it is not yet clear this has translated into a stable return to profitability.

Equity erosion from large net losses

The owners' net loss reached KRW 272.9bn in 2025, with a single quarter (Q4) net loss of KRW 243.0bn far exceeding the scale of the operating loss. As a result, owners' equity shrank sharply from KRW 534.0bn in 2023 to KRW 186.4bn in 2025, while the debt ratio rose from 22.8% to 59.5%. With a weakened capital buffer, a recurrence of large losses could pressure financial stability.

Commercialization delay and early-stage clinical risk

FUCASO's domestic sales launch is targeted for the second half of 2027, limiting near-term earnings contribution, and its import approval and reimbursement status have not yet been finalized.

GCC2005's data are based on a small early-stage patient cohort, raising the possibility that results may not be replicated in larger trials. Artiva's AB-101 is also targeting an FDA filing only in 2029, meaning substantial time remains before it could meaningfully contribute to revenue.

Risk factors

Approval and reimbursement risk

FUCASO's domestic import approval and national health insurance reimbursement status have not yet been finalized, and depending on the review outcome and timing, the targeted second-half-2027 sales launch could be delayed. The details of the health insurance fee-schedule reform implementation could also differ from current plans.

Clinical development risk

GCC2005 and AB-201 are each in Phase 1 trials with small patient cohorts, and AB-101's Phase 3 trial in autoimmune disease is also at an early stage, targeting first-patient dosing in the second half of 2026.

As trials scale up, the possibility of lower response rates or unexpected safety issues emerging cannot be ruled out.

Financial and capital risk

Given that consecutive large net losses in 2024-2025 significantly reduced equity and raised the debt ratio, further one-off losses or expanded clinical/commercialization investment could add financial strain.

Should additional funding be required, the possibility of dilution from an increase in share count should also be considered.

What to watch next

Around November 2026
The Q3 2026 earnings release should be checked to see whether the narrowing operating loss trend continues and whether diagnostic-testing revenue recovers.
December 2026
This marks the scheduled implementation of the health insurance fee-schedule reform; the actual margin improvement from the 45% outsourced-testing fee rate should be verified.
Second half of 2026
Additional clinical data from roughly 18 patients for GCC2005 is scheduled for release, and it should be checked whether the response and complete response rates seen in the initial cohort are maintained.
Second half of 2026
Whether Artiva begins first-patient dosing in the AB-101 Phase 3 trial should be confirmed, as on-schedule progress will affect the targeted 2028 data readout timeline.
Upon announcement of the approval review outcome
The outcome of FUCASO's domestic import approval and reimbursement review should be checked, as it will determine the feasibility of the targeted second-half-2027 sales launch.

Overall view

GC Cell is diversifying its NK, CAR-NK, and CAR-T pipeline on the back of stable cash flow from its diagnostic-testing and bio-logistics businesses, but four consecutive years of revenue decline since 2022 and consecutive large net losses in 2024-2025 have significantly weakened its capital base.

In the first half of 2026, signs of passing a low point emerged, with quarterly operating losses narrowing and owners' net profit turning positive in Q2, though it is still too early to conclude that a stable return to profitability has taken hold.

While the diagnostic-testing segment is expected to see margin improvement from the December fee-schedule reform, the cell therapy segment's direction will hinge on clinical data from pipeline assets such as GCC2005, AB-201, and AB-101, along with the approval and reimbursement process for FUCASO.

Since commercialization revenue contribution is broadly expected only from the second half of 2027 onward, market interpretation of near-term clinical and policy events could influence the stock in the interim.

Readers should continue to monitor the progress of the checkpoints outlined above before forming any investment judgment.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.